English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Preventive screening of tumors is fundamental to prevent their degeneration. The curable rate of colorectal cancer (CRC), identified at stage I is up to 90%. Here the results obtained so far in the clinical validation Protocol, using a device hosting an array of chemoresistive semiconductor gas sensors, are shown. The Protocol has been started in May 2016. The device can identify the difference between the odor of feces from two categories of people: healthy subjects, and subjects affected by high-risk adenomas or tumors. Moreover, we are calibrating the instrument so that it can also recognize low-risk adenomas. The tests are compared to fecal occult blood test and colonoscopy (gold-standard) results. The tests are still ongoing since 31 December 2018.

DH2.4 - Chemoresistive sensors for colorectal cancer preventive screening through fecal odor: double-blind approach